Vilarrasa, E, Molina-Leyva, A, Martín, V, Coak, E, Truman, I, Wallinger, H, Richardson, C, Martorell, A. Unmet clinical needs, burden of disease and treatment patterns in hidradenitis suppurativa: Real-world experience from Spain. Jeadv Clinical Practice. 2024; 3(1)DOI:10.1002/jvc2.237. PMID:. IF:(Q/D).

Vilarrasa, E, Nicolau, J, de la Cueva, P, Goday, A, Gallardo, F, Martorell-Calatayud, A, Carrascosa, JM. [Translated article] Glucagon-Like Peptide-1 Agonists for Treating Obesity in Patients With Immune-Mediated Skin Diseases. Actas Dermo-Sifiliograficas. 2024; 115(1)DOI:10.1016/j.ad.2023.10.019. PMID:37918631. IF:(Q/D).

Fernández-figueras, MT, Pérez-muñoz, N, Puig, L, Posada-caez, R, Victoria, RB, Henriquez, M, Musulen, E. Predictors of Local Invasion in Infiltrative Basal Cell Carcinoma: Tumour Budding Outperforms the WHO Subtyping. ACTA DERMATO-VENEREOLOGICA. 2024; 104DOI:10.2340/actadv.v104.40172. PMID:38956962. IF:3.700(Q1/2D).

Puig, L, Tsai, TF, Soriano, ER, Bhutani, T, Miller, M, Kollmeier, AP, Li, S, You, Y, Li, HW, Patel, H, Lavie, F, Gooderham, M, Londoño, A, Lebwohl, M, Nash, P. SAFETY IN PATIENTS WITH LATENT TUBERCULOSIS WHO RECEIVED CONCOMITANT ANTITUBERCULOSIS MEDICATIONS: ANALYSIS OF 11 STUDIES OF GUSELKUMAB IN PSORIATIC DISEASE. ACTA DERMATO-VENEREOLOGICA. 2024; 104DOI:. PMID:. IF:3.700(Q1/2D).

Balado-Simo, P, Morgado-Carrasco, D, Gomez-Armayones, S, Lopez-Ferrer, A, Barco, D, Ferrándiz-Pulido, C, Podlipnik, S. An Updated Review of Topical Tretinoin in Dermatology: From Acne and Photoaging to Skin Cancer. Journal of Clinical Medicine. 2025; 14(22)DOI:10.3390/jcm14227958. PMID:41302994. IF:2.900(Q1/2D).

Jiménez-Sánchez, A, Moreno-Arrones, OM, Béa-Ardebol, S, Mayo-Martínez, F, Pérez-Pastor, G, Torres-Navarro, I, Bonfill-Orti, M, Ruiz-Salas, V, Masferrer, E, Martos-Cabrera, L, Deza, G, Cabrera, RFDM, Feal, C, Turrión-Merino, L, Toll, A, Pérez, CA, Estrada, RB, Yébenes, M, Galiano-Mejías, S, Jiménez-Gallo, D, Ferrandiz-Pulido, C, Florez, A, Hernández-Hernández, N, Rios-Buceta, L, Sanmartín, O, Blanco, CC, Jaka, A, Just-Sarobé, M, Conde-Taboada, A, Arenal, MM, Vargas-Laguna, E, León, IA, Leal, L, Montalvo, SM, Polo, I, Hernández-Marín, B, Soria, A, Delgado-Jiménez, Y, Rodriguez-Jiménez, P. Response to Sonidegib in Advanced Basal Cell Carcinomas by Histological Subtype: A Real-World Cohort. INTERNATIONAL JOURNAL OF DERMATOLOGY. 2025; 64(11)DOI:10.1111/ijd.17896. PMID:40468572. IF:3.200(Q1/3D).

Mansilla-Polo, M, García-Moronta, C, Fernández-Crehuet, P, Garbayo-Salmons, P, Pons-Benavent, M, Aguilar-González, L, Jiménez-Gallo, D, Alcalá-García, R, Martín-Ezquerra, G, Martorell, A, Mahiques-Santos, L, Alfageme-Roldán, F, Escutia-Muñoz, B, Sahuquillo-Torralba, A, Fayos-Gregori, R, Soto-Moreno, A, Sánchez-Gutiérrez, I, Botella-Estrada, R, Vilarrasa, E, Molina-Leyva, A. Long-Term Effectiveness and Safety of Bimekizumab in Patients with Moderate to Severe Hidradenitis Suppurativa Under Real Clinical Practice Conditions: The Importance of Combined Treatment in Hurley III Patients and Potential Factors Associated with Complete Response. Dermatology and Therapy. 2025; 15(11)DOI:10.1007/s13555-025-01521-z. PMID:40866757. IF:4.200(Q1/1D).

Papp, KA, Puig, L, Beecker, J, Chandran, V, Claveau, J, Cortes, J, Dutz, J, Hornick, NI, Juergens, RA, Melosky, B, Patel, AB, Sauder, MB, Sehdev, S, Sibaud, V, Snow, SL. Systemic treatment of immune checkpoint inhibitor-induced psoriasis: Inference-based guidance. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2025; 39(11)DOI:10.1111/jdv.20809. PMID:40685883. IF:8.000(Q1/1D).

Carmona-Rocha, E, Torné, CD, Alonso, AML, Puig, L. [Translated article] Methotrexate-Induced Gouty Arthritis in Psoriatic Patient. Actas Dermo-Sifiliograficas. 2025; 116(10)DOI:10.1016/j.ad.2025.10.010. PMID:41067613. IF:(Q/D).

Fernández, CPH, Borrego, L, Arnau, AMG, Sánchez, TS, Carrillo, JMC, Ninet, VZ, Baldrich, ES, Miquel, FJM, Salvador, JFS, Guijarro, SC, Gilo, AS, García, PM, Triviño, FN, Romero, FT, Serna, MR, Ninot, GM, González, IR, de la Fuente, EG, Nieto, MAP, Guillén, PSP, Pérez, JS, Rodríguez, JJP, Ortega, MEG, Pérez, RG, Doval, IG, Descalzo, MAG. [Translated article] Should Hydroxyisohexyl 3-Cyclohexene Carboxaldehyde (Lyral®) Still be Part of the Baseline Series?. Actas Dermo-Sifiliograficas. 2025; 116(10)DOI:10.1016/j.ad.2025.10.016. PMID:41076186. IF:(Q/D).

Mateu-Arrom, L, Nogueira, XAV, Puig, L, Spertino, J. Predictors of response to omalizumab and relapse in chronic spontaneous Urticaria: a narrative review focusing on parameters available in routine clinical practice. Frontiers In Allergy. 2025; 6DOI:10.3389/falgy.2025.1688464. PMID:41246132. IF:(Q/D).

Torres, T, Puig, L. Letter to the Editor Regarding: "Cardiovascular and Kidney Outcomes After Systemic Treatment for Plaque Psoriasis: A Systematic Review and Network Meta-Analysis". Dermatology and Therapy. 2025; 15(10)DOI:10.1007/s13555-025-01513-z. PMID:40779225. IF:4.200(Q1/1D).

Pinter, A, Brnabic, A, Trovato, E, Puig, L, Carrascosa, JM, Boye, T, Megna, M, Sabatino, S, de la Torre, I, Maul, JT. Comparative Effectiveness and Durability of Biologics Through 24 Months for Patients with Moderate-to-Severe Psoriasis: Results from the International, Observational Psoriasis Study of Health Outcomes (PSoHO). Dermatology and Therapy. 2025; 15(10)DOI:10.1007/s13555-025-01494-z. PMID:40699538. IF:4.200(Q1/1D).

Bouhatous, YM, Bredrup, C, Maurer, A, Mirakovska, L, Foster, A, Kosaki, K, Jost, C, Demoulin, JB, Luu, M, Vabres, P, Kurtz, JE, Schaefer, E, Guimier, A, Cormier-Daire, V, Lim, D, Thompson, S, Olson, L, Kwon, HR, Aguirre-Rodriguez, C, Hernandez-Dorronsoro, U, Martinez-Soroa, I, Iznardo, H, Mascaro, JMJ, Baselga, E, Kalantari, S, Mussa, A, Gazzin, A, Carli, D, Svinvik, I, Mutlu-Albayrak, H, Bluefeather, S, Zarate, Y, Takenouchi, T, Naicker, T, Chateau, A, Gokhul, A, Dube-Pule, A, Haniffa, M, Peitee, WO, Nordgren, A, Carpentier, M, Binquet, C, Briffaut, AS, Bal, L, Pond, D, Rustad, CF, Bardou, M, Faivre, L. 'Knowing and Treating Kosaki/Penttinen syndrome' international collaborative consortium: recommendations for follow-up, natural history and a real-life observational study about safety and efficacy profile of tyrosine kinase inhibitors. JOURNAL OF MEDICAL GENETICS. 2025; 62(10)DOI:10.1136/jmg-2024-110600. PMID:40707250. IF:3.700(Q2/3D).

Yosipovitch, G, Lio, PA, Rosmarin, D, Legat, FJ, Serra-Baldrich, E, Carrascosa, JM, Bardolet, L, Crane, H, Casillas, M, Pierce, E, Zhong, JL, Elmaraghy, H, Ständer, S. Lebrikizumab Improved Itch Symptoms and Reduced Itch Interference on Sleep over 52 Weeks in Patients with Moderate-to-Severe Atopic Dermatitis in Two Phase 3 Trials. DERMATOLOGY. 2025; 241(4)DOI:10.1159/000547142. PMID:40602386. IF:2.700(Q2/4D).

Puig, L. Icotrokinra in psoriasis: IL-23 receptor antagonism via oral peptide with biologic-level efficacy. LANCET. 2025; 406(10510)DOI:10.1016/S0140-6736(25)01675-7. PMID:40976247. IF:88.500(Q1/1D).

Ferrer, AL, Macias, HC, Sanz, LP, Alonso, AL. Ten-Year Experience in the Joint Dermatology-Rheumatology Approach to Patients With Psoriatic Arthritis. Actas Dermo-Sifiliograficas. 2025; 116(8)DOI:10.1016/j.ad.2025.06.013. PMID:40570946. IF:(Q/D).

Puig, L, Sewerin, P, Schuster, C, Ng, KJ, Papadimitropoulos, M, Gadagamma, S, Nuñez, M, Lampropoulou, A. Real-World Evidence for Ixekizumab in the Treatment of Psoriasis, Psoriatic Arthritis, and Axial Spondyloarthritis: Systematic Literature Review 2022-2023. ADVANCES IN THERAPY. 2025; 42(9)DOI:10.1007/s12325-025-03258-9. PMID:40676380. IF:4.000(Q1/3D).

Kokolakis, G, Vilarrasa, E, Garg, A, Alarcon, I, Go, M, Newbold, G, Mamareli, A, Richardson, C, McGrath, BM, Guillem, P. Patient Perspectives on the Impact of Living With Hidradenitis Suppurativa: Results From the Global 'HS Uncovered' Burden of Disease Survey. Jeadv Clinical Practice. 2025; 4(4)DOI:10.1002/jvc2.70071. PMID:. IF:(Q/D).

Papp, KA, Lebwohl, MG, Puig, L, Ohtsuki, M, Beissert, S, Gooderham, M, Amin, AZ, Wu, TS, Rubant, S, Bialik, B, Ashley, D, Soliman, AM, Chen, MM, Blauvelt, A. Long-Term Safety and Efficacy of Risankizumab to Treat Moderate-to-Severe Plaque Psoriasis: Final LIMMitless Phase 3, Open-Label Extension Trial Results. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY. 2025; 26(5)DOI:10.1007/s40257-025-00964-6. PMID:40728772. IF:8.800(Q1/1D).